Lauren Feldman 10/06/2023 at 6:35 pm
Genetic Engineering and Biotechnology News (October 6, 2023) AI-Based Drug Discovery Company Atomwise Sets Its Sights on Inflammatory Disease Market
Atomwise, which has historically used its AI platform to help drug developers identify compounds for their pipelines, is entering a new phase of its journey. This week, it announced the nomination of its first AI-driven development candidate, a small molecule focused on TYK2 inhibition, officially marking its transition into a pharmaceutical company.
BioPhamaReporter (October 6, 2023) Envozyne Raises $81m to leverage AI in drug discovery
Evozyne has announced the closing of an $81 million series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
Interesting Engineering (October 4, 2023) Bioprinted skin heals severe wounds in pigs, humans are next
Scientists from the Wake Forest Institute for Regenerative Medicine have created a bioprinted skin that functions like natural skin. It can be used to treat wounds, burns, and various other types of skin injuries. Made from six types of body cells, the bioprinted skin comprises all three layers — hypodermis, epidermis, and dermis- that make up the real human skin. To test the safety and efficacy of their approach, the researchers bioprinted pig skin grafts and transplanted those onto full-thickness wounds in pigs. It resulted in improved wound closure and skin regeneration in the animal.
Wired (October 3, 2023) A Lab Just 3D-Printed a Neural Network of Living Brain Cells
Scientists at Monash University in Melbourne, Australia, have printed living neural networks composed of rat brain cells that seem to mature and communicate like real brains do. Researchers want to create mini-brains partly because they could someday offer a viable alternative to animal testing in drug trials and studies of basic brain function. At the start of 2023, the US Congress passed an annual spending bill pushing scientists to reduce their use of animals in federally funded research, following the signing of the US Food and Drug Administration’s Modernization Act 2.0, which allowed high-tech alternatives in drug safety trials. Rather than testing new drugs on thousands of animals, pharmaceutical companies could apply them to 3D-printed mini-brains—in theory. There are still complexities to iron out before this moves from proof of concept to standard lab practice.
Fierce Pharma (October 3, 2023) AI drug hunter Exscientia chops down ‘rapidly emerging pipeline’ to focus on 2 main oncology programs
AI drug discovery technology can churn out a lot of promising candidates, but, at some point, the reality of the biotech world hits all companies: Only the best of the best should be advanced. Exscientia is paring back its “rapidly emerging pipeline” to focus on the highest value possibilities.
- You must be logged in to reply to this topic.